Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival We performed a single-institution retrospective analysis of patients with R/M HNSCC treated ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...
Cetuximab biosimilar is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Penile Cancer. According to GlobalData, Phase I drugs for Penile Cancer does ...
Defense mechanisms are rooted in Freud’s theory of personality.According to his model, the mind has three dueling forces: the id (unconscious and primitive urges for food, comfort, and sex), the ...
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
Here, we review the mechanism(s) of action of erlotinib, as well as the results of Phase I, II and III trials with this drug in NSCLC, which have led to the worldwide approval of erlotinib ...
Jan. 24, 2025 — A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of ...
A joint research group team led by Sayuri Tsukahara and Tetsuji Kakutani of the University of Tokyo has clarified a mechanism of how retrotransposons, genetic elements that can "jump around ...
Jan. 27, 2025 — Researchers have uncovered a significant connection between elevated uric acid levels and life-threatening outcomes in children with severe ...